Bristol-Myers Squibb Co. (BMY) is set to face a pivotal FDA decision on March 6, 2026, regarding its supplemental New Drug Application for Sotyktu in the expanded indication of treating adults with active psoriatic arthritis.
Sotyktu (deucravacitinib), a first-in-class oral tyrosine kinase 2 (TYK2) inhibitor, was FDA-approved in September 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The drug works by selectively blocking TYK2, a key signaling enzyme mediating IL-23, IL-12, and Type I interferon pathways involved in immune and inflammatory responses.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com